Nanobiotix S.A.
NBTX
Updated: 23/09/2026, 05:14:49
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.
No summaries found.
- Share price
- $35.15
- Market cap
- $1.78B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Laurent Levy
- Employees
- 97
- IPO date
- 11/12/2020
- Beta
- 0.5679999999999999
- Last dividend
- $0.00
- Day range
- $34.07 – $35.80
- 52-week range
- $13.30 – $57.14
- 1-day performance
- 1.88%
- 1-year performance
- 164.29%
- Current drawdown (1Y)
- -38.48%
- CIK
- 0001760854
- CUSIP
- 63009J107
- ISIN
- US63009J1079
- Created
- 07/12/2025, 05:24:35
- Last update
- 23/09/2026, 05:14:49
Track Nanobiotix S.A. with an AI analyst
See which prediction-market events move NBTX, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
Seeking Alpha • STOCK • 12/06/2026, 18:58:37
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
GlobeNewsWire • STOCK • 02/06/2026, 18:30:00
Nanobiotix Joins the Euronext Tech Leaders Index
GlobeNewsWire • STOCK • 02/06/2026, 04:30:00
NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
GlobeNewsWire • STOCK • 22/05/2026, 18:15:00
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
GlobeNewsWire • STOCK • 21/05/2026, 11:30:00
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
GlobeNewsWire • STOCK • 21/05/2026, 04:30:00
Nanobiotix Announces Launch of Global Follow-On Offering
GlobeNewsWire • STOCK • 20/05/2026, 20:19:00
How Nanobiotix Got Wall Street's Attention By Using Physics To Battle Cancer
Investors Business Daily • STOCK • 20/05/2026, 10:00:31
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
GlobeNewsWire • STOCK • 17/05/2026, 12:15:00
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
GlobeNewsWire • STOCK • 04/05/2026, 19:29:00
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
GlobeNewsWire • STOCK • 20/04/2026, 04:30:00
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 01/04/2026, 16:02:05